Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 5
2005 13
2007 7
2008 1
2009 4
2010 10
2011 4
2012 14
2013 15
2014 24
2015 17
2016 14
2017 8
2018 8
2019 12
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

142 results
Results by year
Filters applied: . Clear all
Page 1
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Valle J, et al. Among authors: Madhusudan S. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721. N Engl J Med. 2010. PMID: 20375404 Free article. Clinical Trial.
DNA damage repair in breast cancer and its therapeutic implications.
Ali R, Rakha EA, Madhusudan S, Bryant HE. Ali R, et al. Among authors: Madhusudan S. Pathology. 2017 Feb;49(2):156-165. doi: 10.1016/j.pathol.2016.11.002. Epub 2016 Dec 26. Pathology. 2017. PMID: 28034453 Review.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Modi S, et al. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825192 Clinical Trial.
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Neoptolemos JP, et al. JAMA. 2012 Jul 11;308(2):147-56. doi: 10.1001/jama.2012.7352. JAMA. 2012. PMID: 22782416 Clinical Trial.
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW; European Study Group for Pancreatic Cancer. Neoptolemos JP, et al. JAMA. 2010 Sep 8;304(10):1073-81. doi: 10.1001/jama.2010.1275. JAMA. 2010. PMID: 20823433 Clinical Trial.
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial.
Golan T, Geva R, Richards D, Madhusudan S, Lin BK, Wang HT, Walgren RA, Stemmer SM. Golan T, et al. Among authors: Madhusudan S. J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):871-879. doi: 10.1002/jcsm.12331. Epub 2018 Jul 27. J Cachexia Sarcopenia Muscle. 2018. PMID: 30051975 Free PMC article. Clinical Trial.
Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
Green AR, Aleskandarany MA, Ali R, Hodgson EG, Atabani S, De Souza K, Rakha EA, Ellis IO, Madhusudan S. Green AR, et al. Among authors: Madhusudan S. Cancer Immunol Res. 2017 Apr;5(4):292-299. doi: 10.1158/2326-6066.CIR-16-0195. Epub 2017 Mar 2. Cancer Immunol Res. 2017. PMID: 28254786 Free article.
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA; RAINFALL Study Group. Fuchs CS, et al. Lancet Oncol. 2019 Mar;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5. Epub 2019 Feb 1. Lancet Oncol. 2019. PMID: 30718072
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
Naidoo K, Wai PT, Maguire SL, Daley F, Haider S, Kriplani D, Campbell J, Mirza H, Grigoriadis A, Tutt A, Moseley PM, Abdel-Fatah TMA, Chan SYT, Madhusudan S, Rhaka EA, Ellis IO, Lord CJ, Yuan Y, Green AR, Natrajan R. Naidoo K, et al. Among authors: Madhusudan S. Mol Cancer Ther. 2018 Jan;17(1):306-315. doi: 10.1158/1535-7163.MCT-17-0760. Epub 2017 Nov 13. Mol Cancer Ther. 2018. PMID: 29133620 Free PMC article.
Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention.
Ali R, Al-Kawaz A, Toss MS, Green AR, Miligy IM, Mesquita KA, Seedhouse C, Mirza S, Band V, Rakha EA, Madhusudan S. Ali R, et al. Among authors: Madhusudan S. Cancer Res. 2018 Dec 15;78(24):6818-6827. doi: 10.1158/0008-5472.CAN-18-0633. Epub 2018 Oct 8. Cancer Res. 2018. PMID: 30297533 Free article.
142 results
Jump to page
Feedback